Compare AbCellera Biologics Inc (ABCL) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs LyondellBasell Industries NV — how do they compare? AbCellera Biologics Inc trades at $7.12 (market cap $2.35B), while LyondellBasell Industries NV trades at $56.28 (market cap $17.62B). The key difference: LyondellBasell Industries NV is far larger — about 7.5× AbCellera Biologics Inc's market cap, and LyondellBasell Industries NV pays a 7.55% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | LYB | |
|---|---|---|
Market Cap | $2.35B | $17.62B |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $82.38 |
52-Week Low | $2.78 | $42.28 |
Enterprise Value | $1.99B | $29.24B |
Dividend Yield | — | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
LyondellBasell (LYB) trades at $54.61, up 2.33% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$745M in 2025 with revenue declining to $30.15B, though it beat EPS estimates in two of the last three quarters. Recent news highlights a packaging collaboration with Mondelez and upcoming Q2 2026 earnings on July 31. Cash flow remains positive with $61M net inflow in 2025, while debt-to-asset ratio increased to 38.18%.
Outlook is mixed: analyst consensus price target of $73.11 suggests 34% upside, supported by cost-cutting and recycling initiatives, but persistent margin pressures and high debt pose risks. Investors should weigh the value opportunity (P/S of 0.57) against earnings volatility and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
